Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a report issued on Monday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Senseonics in a report on Friday, November 15th.

Senseonics Price Performance

Shares of NYSE:SENS opened at $0.31 on Monday. The firm has a market capitalization of $184.25 million, a PE ratio of -2.38 and a beta of 0.77. Senseonics has a 1 year low of $0.28 and a 1 year high of $0.75. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The firm’s 50-day moving average is $0.33 and its two-hundred day moving average is $0.38.

Institutional Investors Weigh In On Senseonics

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Senseonics by 0.7% during the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after buying an additional 155,715 shares during the period. Geode Capital Management LLC grew its holdings in Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after acquiring an additional 179,103 shares in the last quarter. Symmetry Partners LLC purchased a new stake in shares of Senseonics in the 3rd quarter valued at approximately $164,000. Cubist Systematic Strategies LLC raised its holdings in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares during the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.